NIH-Funded ACTIV/ACTIV-Associated Clinical Trials

 
 
Company Therapeutic Class Administration New/
Repurposed		 Status/Estimated
End Date

ACTIV-1 Inpatient
AbbVie Cenicriviroc Immune Modulator Oral New Ended/Failed interim analysis
BMS Orencia® (abatacept) Immune Modulator Intravenous Repurposed Enrollment closed/Awaiting topline results
Janssen Remicade® (Infliximab) Immune Modulator Intravenous Repurposed Enrollment closed/Awaiting topline results

ACTIV-2 Outpatient
AstraZeneca AZD7442 Monoclonal Antibody Cocktail Intramuscular New Enrollment closed due to company decision
AstraZeneca AZD7442 Monoclonal Antibody Cocktail Intravenous New Enrollment closed/Awaiting topline results
Brii Biosciences Brii-196 & Brii-198 Monoclonal Antibody Cocktail Intravenous New Ended/Efficacy shown/EUA filed
Bristol Myers Squibb BMS-986414 and BMS-986413 (also known as C135-LS and C144-LS) Monoclonal Antibody Cocktail Subcutaneous Injection New Ended/Graduation criteria unmet
Eli Lilly LY-CoV-555 Monoclonal Antibody Single Intravenous New Ended/Efficacy shown/EUA granted
SAB Biotherapeutics SAB-185 Polyclonal antibody Intravenous New Passed interim analysis/Enrollment closed due to operational futility
Sagent Camostat Mesylate Antiviral Oral Repurposed Ended/Graduation criteria unmet
Synairgen SNG001 IFN-beta Immune Modulator Inhaled Repurposed Enrollment closed due to operational futility

ACTIV-3 Inpatient
AstraZeneca AZD7442 Monoclonal Antibody Cocktail Intravenous New Enrollment closed/Awaiting topline results
Brii Biosciences Brii-196 & Brii-198 Monoclonal Antibody Cocktail Intravenous New Ended/Graduation criteria unmet
Eli Lilly LY-CoV-555 Monoclonal Antibody Single Intravenous New Ended/Graduation criteria unmet
Giliad/NeuroRx ZyesamiTM (aviptadil acetate) and Veklury® (remdesivir)  Immune Modulator/Antiviral Intravenous Repurposed Continuing enrollment/Q4 2022
GSK-Vir VIR-7831 Monoclonal Antibody Single Intravenous New Ended/Graduation criteria unmet
Molecular Partners/Novartis Ensovibep (MP0420) DARPin Intravenous New Ended/Graduation criteria unmet
Pfizer PF-07304814 Protease inhibitor Intravenous New Ended due to company decision

ACTIV-4

Outpatients
BMS/Pfizer Eliquis ® (apixaban) Anticoagulant Oral Repurposed Enrollment closed due to operational futility
BMS/Pfizer Aspirin Antiplatelet Oral Repurposed Enrollment closed due to operational futility

Inpatients
Other Un-fractionated (UF) Heparin Anticoagulant Intravenous Repurposed Ended/Efficacy shown
Other Unfractionated Heparin and P2Y12 Inhibitors Anticoagulant Intravenous Repurposed Continuing enrollment/Q2 2022
Other Low Molecular Weight (LMW) Heparin Anticoagulant Injection Repurposed Ended/Efficacy shown
Other Therapeutic Heparin and P2Y12 Inhibitors Anticoagulant Intravenous and Oral Repurposed Ended/Failed interim analysis
Other Prophylactic Heparin and P2Y12 Inhibitors Anticoagulant Intravenous and Oral Repurposed Continuing enrollment/Passed interim analysis/Q2 2022
Novartis Crizanlizumab Monoclonal Antibody Single Intravenous  Repurposed Continuing enrollment/Q1 2023
Various SGLT2i Sodium/glucose cotransporter-2 inhibitors Oral Repurposed Continuing enrollment/Q1 2023

Convalescent
BMS/Pfizer Eliquis ® (apixaban) Anticoagulant Oral Repurposed Continuing enrollment/Passed interim analysis/Q4 2022

Host Tissue
Constant Therapeutics TXA127 Mas Receptor Agonist IV New Ended/Failed interim analysis
Trevena TRV027 AT1R Beta-arrestin Agonist IV New Ended/Failed interim analysis
Rigel Fostamatinib Syk Inhibitor Oral Repurposed Continuing enrollment/Q3/4 2022

ACTIV-5 Inpatient
AbbVie/Boehringer Ingelheim SkyrisiTM (risankizumab) Immune Modulator Intravenous Repurposed Enrollment closed/Awaiting topline results
Humanigen Lenzilumab Immune Modulator Intravenous New Enrollment closed/Awaiting topline results
Alexion Danicopan

Factor D Inhibitor

 Oral New Enrollment closed/Awaiting topline results

ACTIV-6 Outpatient
Apotex Fluvoxamine Immune Modulator/Antiviral Oral Repurposed Continuing enrollment/Q2 2022
GlaxoSmithKline Fluticasone Immune Modulator Oral Repurposed Enrollment closed/Awaiting topline results
Ingenus Ivermectin 400mcg Immune Modulator/Antiviral Oral Repurposed Enrollment closed/Awaiting topline results
Ingenus Ivermectin 600mcg Immune Modulator/Antiviral Oral Repurposed Continuing enrollment/Q1 2023

ACTIV-Associated

Adaptive COVID-19 Treatment Trial (ACTT) Inpatient
Gilead Veklury® (remdesivir) Antiviral Intravenous Repurposed Ended
Gilead/Eli Lilly Veklury® (remdesivir) and Olumiant® (baricitinib) Antiviral/Anti-Inflammatory Intravenous/Oral Repurposed Ended
Gilead/Merck KGaA Veklury® (remdesivir) and Rebif® (IFN-beta ) Antiviral/Immune Modulator Injection Repurposed Ended
Gilead/Eli Lilly/Other Veklury® (remdesivir) and Olumiant® (baricitinib) or Dexamethasone Antiviral/Anti-Inflammatory/
Immune Modulator		 Intravenous/Oral Repurposed Ended

Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC)
Gilead/Other Veklury® (remdesivir) and Hyperimmune
Intravenous Immunoglobulin (hIVIG)		 Antiviral Intravenous N/A Ended

Convalescent Plasma in Outpatients with COVID-19 (C3PO)

Other Convalescent Plasma Convalescent Plasma Intravenous N/A Ended

Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients (CONTAIN COVID-19)
Other Convalescent Plasma Convalescent Plasma Intravenous N/A Ended

Passive Immunity Trial of Our Nation (PassItOn) Inpatient
Other Convalescent Plasma Convalescent Plasma Intravenous N/A Ended

This page last reviewed on April 26, 2022